European Archives - Page 717 of 1391 - European Medical Journal

This site is intended for healthcare professionals

Continue
25 Oct 2022

Striving for more: personalizing care in patients with psoriatic disease

Striving for more: personalizing care in palients with psoriatic disease. Educational objectives: Understand what patients need and expect from their treatment journey from its outset. Drive the importance of collecting patient reported outcomes on registries and analysing data by gender/age. Consider shared decision-making as essential throughout a patient’s joumey, understanding how it can further treatment personalisation and patient outcomes
1 Mins
25 Oct 2022

Tumour Organoids from Multifocal Metastatic Colorectal Cancers for Personalised Oncology

Patients with colorectal cancer (CRC) have limited systemic treatment options compared to other major cancer types.1 Tumour heterogeneity is a major cause of treatment failure.
8 Mins
25 Oct 2022

Review of the European Society for Medical Oncology (ESMO) Congress 2022

THREE years after the last in-person European Society for Medical Oncology (ESMO) Congress, the 2022 congress welcomed nearly 23,000 participants in Paris, France, as well as 5,000 online. The purpose of the congress was a celebration of being back together, and of collaboration between all healthcare professionals wanting to improve survival times for patients.
October 2022

EMJ Oncology 10.1 2022

The latest issue of EMJ Oncology is out now featuring engaging content, including a review article examining colorectal cancer during pregnancy and an analysis of optimal immunohistochemical cut-off markers in breast cancer.
8 Mins
25 Oct 2022

Precision Medicine and Next-Generation Sequencing Diagnostic at European Society for Medical Oncology Congress 2022: The Unbreakable Bond

This article covers symposia that took place from 9th–13th September, 2022 as part of the European Society for Medical Oncology (ESMO) Congress 2022.
1 Mins
25 Oct 2022

Does Hepatitis C Independently Increase the Risk of Colorectal Adenoma?

Hepatitis C virus (HCV) infection has been associated with extrahepatic malignancies such as colorectal carcinoma (CRC). The majority of CRCs arise from adenomatous polyps, and it is not known if HCV infection influences the growth of these pre-cancerous lesions.
4 Mins
25 Oct 2022

Immunotherapy in Non-small Cell Lung Cancer: Current and Future Use

EXPLORING the current state of use of immunotherapies in the treatment of non-small cell lung cancer (NSCLC) and looking to future immunotherapeutic pathways, three expert speakers presented a session at European Society for Medical Oncology (ESMO) Congress 2022, on the 12th of September.
2 Mins
25 Oct 2022

Epidermal Growth Factor Receptor Mutation Testing from Pleural Effusions of Patients with Advanced Lung Adenocarcinoma in Serbia

High incidence of lung cancer in Serbia is derived from high smoking rates, the lack of a nationwide screening programme, and the presence of environmental risk factors. By histology, adenocarcinoma accounts for approximately 50% of all lung cancer cases, with approximately 60% of new diagnoses already in advanced disease stages, where targeted therapies and immunotherapy are indicated.
1 Mins
25 Oct 2022

Assessment of Early Detection by Multi-omics-Based Liquid Biopsy in Lung Cancer: A Prospective Study (ASCEND-LUNG)

Lung cancer is the leading cause of cancer deaths worldwide, with a global estimation of 2.2 million new cases and 1.8 million deaths in 2020. Low-dose spiral CT-based screening has shown significant mortality reduction of lung cancer in randomised clinical trials. However, the high false-positive results (around 96%) will lead to high rates of overdiagnosis.
2 Mins
25 Oct 2022

MammaPrint® 10-Year Follow Up Results from a German Breast Cancer Cohort Study

The MammaPrint® (MP) 70-gene test is utilised in personalised treatment planning for patients with early-stage breast cancer (EBC) with either node-positive or node-negative disease and categorises tumours as high risk (MP-HR; MP index: –1–≤0) or low risk (MP-LR; MP index: >0–+1).
We’ve noticed you’re accessing
from North/South America.